Biotie announces start of tozadenant Phase 3 study in Parkinson’s disease
21 July 2015 | By Victoria White
A Phase 3 study of tozadenant in patients with Parkinson's disease experiencing levodopa related end-of-dose "wearing-off" has started...
List view / Grid view
21 July 2015 | By Victoria White
A Phase 3 study of tozadenant in patients with Parkinson's disease experiencing levodopa related end-of-dose "wearing-off" has started...
20 February 2015 | By Biotie
Biotie has announced further detail on its clinical development plan for tozadenant, an adenosine A2a antagonist in development for Parkinson's disease (PD)...
17 February 2015 | By Biotie
COMP has issued a positive opinion recommending orphan drug designation for Biotie's BTT1023 for the treatment of primary sclerosing cholangitis (PSC)...